相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy
Massimo Franchini et al.
VOX SANGUINIS (2021)
IgA dominates the early neutralizing antibody response to SARS-CoV-2
Delphine Sterlin et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma
Esam I. Azhar et al.
VOX SANGUINIS (2021)
Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States
Christina L. Dean et al.
TRANSFUSION (2020)
Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
Izabela Ragan et al.
PLOS ONE (2020)
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Kai Duan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light
Marion C. Lanteri et al.
TRANSFUSION (2020)
Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment
Shawn D. Keil et al.
VOX SANGUINIS (2020)
Points to consider in the preparation and transfusion of COVID-19 convalescent plasma
Jay Epstein et al.
VOX SANGUINIS (2020)
Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma A proof-of-concept, single-arm, multicenter trial .
Cesare Perotti et al.
HAEMATOLOGICA (2020)
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19
Thomas Hueso et al.
BLOOD (2020)
Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countries
Evan M. Bloch et al.
VOX SANGUINIS (2020)
Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks
Daniel Stadlbauer et al.
TRANSFUSION (2020)
Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura
Olivier Garraud et al.
TRANSFUSION AND APHERESIS SCIENCE (2019)
Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura
R. Herbrecht et al.
VOX SANGUINIS (2018)
Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro
Andrew P. Cap et al.
TRANSFUSION (2016)
Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies
C. Geisen et al.
VOX SANGUINIS (2016)
Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation
Jacques Cinqualbre et al.
TRANSFUSION (2015)
Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept™) over a 5-year period of extensive delivery
V. Bost et al.
VOX SANGUINIS (2015)
Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction
Jose Coene et al.
TRANSFUSION (2014)
Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment - A comparative study
Bela Balint et al.
TRANSFUSION AND APHERESIS SCIENCE (2013)
Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection
Hoi K. Wong et al.
TRANSFUSION (2010)
Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at-30°C
D. J. Bihm et al.
VOX SANGUINIS (2010)
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura
Paul D. Mintz et al.
TRANSFUSION (2006)
Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function
Yasmin Singh et al.
TRANSFUSION (2006)
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies
P de Alarcon et al.
TRANSFUSION (2005)
分享论文
